Adagene (ADAG) vs Organigram Global (OGI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Adagene (ADAG) has outperformed Organigram Global (OGI) over the past year, gaining 17.0% versus a loss of 49.1%. Over five years, ADAG leads with a -82.6% price change compared with -90.1% for OGI. Adagene is the larger company by market cap ($138.3 million vs $133.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADAG | OGI |
|---|---|---|
| Share price | $2.06 | $0.9267 |
| Market cap | $138.32M | $133.59M |
| 1-day change | -14.17% | -0.53% |
| YTD return | +8.99% | -44.84% |
| 1-year return | +17.05% | -49.08% |
| 5-year return | -82.60% | -90.10% |
| P/E ratio (TTM) | — | 2.16 |
| Forward P/E | — | 38.61 |
| EPS (TTM) | $-0.38 | $0.43 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $7.67M | — |
| Revenue growth (YoY) | +7332.76% | — |
| Net income (latest FY) | $-17.61M | — |
| Operating margin | -279.48% | — |
| Net margin | -229.56% | — |
| 52-week high | $4.85 | $2.24 |
| 52-week low | $1.30 | $0.853 |
| Distance from 52-week high | -57.53% | -58.63% |
| Analyst consensus | none | buy |
| Avg. price target upside | +381.07% | — |
| Average volume | 286.63K | 855.47K |
| Shares outstanding | 67.14M | 144.15M |
| Employees | 128 | 1,139 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ADAG has outperformed OGI by 66.1 percentage points over the past year.
About Adagene
ADAG stock →Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 128 employees
About Organigram Global
OGI stock →Organigram Global Inc. engages in the production and sale of cannabis and cannabis-derived products in Canada.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,139 employees
ADAG vs OGI FAQ
Which is bigger, Adagene or Organigram Global?
Adagene (ADAG) is larger, with a market capitalization of $138.32M compared with $133.59M for Organigram Global (OGI).
Which stock has performed better over the past year, ADAG or OGI?
ADAG returned +17.05% over the past 12 months, compared with -49.08% for OGI (price return, excluding dividends). Past performance does not predict future results.
Are Adagene and Organigram Global in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.